181 related articles for article (PubMed ID: 11882619)
1. Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor.
Deddish PA; Marcic BM; Tan F; Jackman HL; Chen Z; Erdös EG
Hypertension; 2002 Feb; 39(2 Pt 2):619-23. PubMed ID: 11882619
[TBL] [Abstract][Full Text] [Related]
2. Bradykinin potentiation by ACE inhibitors: a matter of metabolism.
Tom B; Dendorfer A; de Vries R; Saxena PR; Jan Danser AH
Br J Pharmacol; 2002 Sep; 137(2):276-84. PubMed ID: 12208785
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin.
Marcic BM; Erdös EG
J Pharmacol Exp Ther; 2000 Aug; 294(2):605-12. PubMed ID: 10900238
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of bradykinin and resensitization of its B2 receptor.
Marcic B; Deddish PA; Jackman HL; Erdös EG
Hypertension; 1999 Mar; 33(3):835-43. PubMed ID: 10082496
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
Minshall RD; Tan F; Nakamura F; Rabito SF; Becker RP; Marcic B; Erdös EG
Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
[TBL] [Abstract][Full Text] [Related]
6. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
8. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
9. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
10. Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors.
Marcic B; Deddish PA; Skidgel RA; Erdös EG; Minshall RD; Tan F
J Biol Chem; 2000 May; 275(21):16110-8. PubMed ID: 10748135
[TBL] [Abstract][Full Text] [Related]
11. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.
Deddish PA; Marcic B; Jackman HL; Wang HZ; Skidgel RA; Erdös EG
Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414
[TBL] [Abstract][Full Text] [Related]
12. Effects of the N-terminal sequence of ACE on the properties of its C-domain.
Marcic B; Deddish PA; Jackman HL; Erdös EG; Tan F
Hypertension; 2000 Jul; 36(1):116-21. PubMed ID: 10904022
[TBL] [Abstract][Full Text] [Related]
13. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
15. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
Dumoulin MJ; Adam A; Burnett J; Heublein D; Yamaguchi N; Lamontagne D
Can J Physiol Pharmacol; 2005 Feb; 83(2):166-73. PubMed ID: 15791290
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting-enzyme inhibitors.
Deddish PA; Erdös EE
Lancet; 2002 Sep; 360(9337):947. PubMed ID: 12354491
[No Abstract] [Full Text] [Related]
17. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
18. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
Fryer RM; Segreti J; Banfor PN; Widomski DL; Backes BJ; Lin CW; Ballaron SJ; Cox BF; Trevillyan JM; Reinhart GA; von Geldern TW
Br J Pharmacol; 2008 Mar; 153(5):947-55. PubMed ID: 18084312
[TBL] [Abstract][Full Text] [Related]
19. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors.
Chen Z; Tan F; Erdös EG; Deddish PA
Hypertension; 2005 Dec; 46(6):1368-73. PubMed ID: 16246972
[TBL] [Abstract][Full Text] [Related]
20. Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
Arbin V; Claperon N; Fournié-Zaluski MC; Roques BP; Peyroux J
Br J Pharmacol; 2001 Jun; 133(4):495-502. PubMed ID: 11399666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
